Kazia Therapeutics (KZIA) Equity Average (2018 - 2025)
Kazia Therapeutics (KZIA) has disclosed Equity Average for 5 consecutive years, with -$6.0 million as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Equity Average fell 920.61% year-over-year to -$6.0 million, compared with a TTM value of -$6.0 million through Jun 2025, down 920.61%, and an annual FY2025 reading of -$6.0 million, down 873.43% over the prior year.
- Equity Average was -$6.0 million for Q2 2025 at Kazia Therapeutics, down from $726147.6 in the prior quarter.
- Across five years, Equity Average topped out at $14.0 million in Q2 2022 and bottomed at -$6.0 million in Q2 2025.
- Average Equity Average over 4 years is $4.9 million, with a median of $5.7 million recorded in 2023.
- The sharpest move saw Equity Average decreased 23.33% in 2023, then tumbled 920.61% in 2025.
- Year by year, Equity Average stood at $14.0 million in 2022, then fell by 23.33% to $10.7 million in 2023, then plummeted by 93.21% to $726147.6 in 2024, then crashed by 920.61% to -$6.0 million in 2025.
- Business Quant data shows Equity Average for KZIA at -$6.0 million in Q2 2025, $726147.6 in Q2 2024, and $10.7 million in Q2 2023.